Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | STAT3 | P40763 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561125 | 0.92 | SMN1; SMN2 (0.46) | NPC1RAB9AKMT2AMEN1F2 | |
| SCHEMBL562087 | 0.88 | KMT2A (0.45) | NPC1RAB9AKMT2AMEN1F2 | |
| SCHEMBL562353 | 0.87 | NPC1 (0.51) | NPC1RAB9AKMT2AMEN1F2 | |
| SCHEMBL561365 | 0.87 | KMT2A (0.48) | NPC1RAB9AKMT2AMEN1F2 | |
| SCHEMBL561638 | 0.83 | NPC1 (0.43) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL561556 | 0.83 | SMN1; SMN2 (0.48) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL561142 | 0.81 | PTGER1 (0.56) | NPC1RAB9ASMN1; SMN2LMNAPDE4D | |
| SCHEMBL562123 | 0.81 | KMT2A (0.49) | NPC1RAB9AKMT2AMEN1F2 | |
| SCHEMBL561785 | 0.80 | SMN1; SMN2 (0.49) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL561391 | 0.79 | PTGER1 (0.54) | NPC1RAB9AKMT2AMEN1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | claimed |
| EP-2421834-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | disclosed |
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | disclosed |
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | COE DIANE MARY (GB) | 2012-02-09 | — | — | US | disclosed |
| WO-2010122088-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010122088-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035237-A1 | PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS | RYR2, PAICS, CTRC | NPC1 2163/4885RAB9A 1294/4885KMT2A 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.